Genprex Seeks Resale of 15 Million Shares Amidst Gene Therapy Research

Genprex, a clinical-stage gene therapy company, has filed for the resale of 15 million shares. The company is focused on developing therapies for cancer and diabetes, with its lead product candidate, Reqorsa Immunogene Therapy, being evaluated in three clinical trials for non-small cell lung cancer and small cell lung cancer. Genprex is also developing a preclinical diabetes candidate, GPX-002, using the same construct for both Type 1 and Type 2 diabetes.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced plans to resell 15 million shares. The company is focused on developing innovative therapies for cancer and diabetes, with its lead product candidate, Reqorsa Immunogene Therapy, currently being evaluated in three clinical trials for non-small cell lung cancer and small cell lung cancer [1]. Additionally, Genprex is developing a preclinical diabetes candidate, GPX-002, using the same construct for both Type 1 and Type 2 diabetes [2].

Genprex's recent clinical trial results have shown promising outcomes. The company presented positive preclinical data on Reqorsa Gene Therapy at the 2025 AACR Annual Meeting, indicating robust anti-tumor effects in Ras inhibitor-resistant non-small cell lung cancer [1]. Furthermore, Genprex's diabetes gene therapy program, which includes GPX-002, has shown potential for curative therapy in diabetes [2].

The resale of shares comes at a time when Genprex is actively participating in various industry conferences and events to showcase its advancements. The company recently presented at the BIO 2025 International Convention and the 2025 ASCO Annual Meeting, highlighting its clinical trial designs and positive preclinical data [1].

In summary, Genprex's strategic move to resell 15 million shares reflects its confidence in the potential of its gene therapy portfolio. The company's focus on developing life-changing therapies for cancer and diabetes, coupled with its recent positive clinical trial results, positions it as a promising player in the gene therapy market.

References:
[1] https://stockanalysis.com/stocks/gnpx/
[2] https://www.marketbeat.com/stocks/NASDAQ/GNPX/